CN105189786B - 用作治疗癌症的疗法的靶标的falz - Google Patents
用作治疗癌症的疗法的靶标的falz Download PDFInfo
- Publication number
- CN105189786B CN105189786B CN201480026088.2A CN201480026088A CN105189786B CN 105189786 B CN105189786 B CN 105189786B CN 201480026088 A CN201480026088 A CN 201480026088A CN 105189786 B CN105189786 B CN 105189786B
- Authority
- CN
- China
- Prior art keywords
- bptf
- subject
- melanoma
- time point
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Abstract
Description
Claims (20)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361790153P | 2013-03-15 | 2013-03-15 | |
US61/790,153 | 2013-03-15 | ||
PCT/US2014/029986 WO2014145254A2 (en) | 2013-03-15 | 2014-03-15 | Falz for use as a target for therapies to treat cancer |
Publications (3)
Publication Number | Publication Date |
---|---|
CN105189786A CN105189786A (zh) | 2015-12-23 |
CN105189786A8 CN105189786A8 (zh) | 2018-01-12 |
CN105189786B true CN105189786B (zh) | 2018-04-03 |
Family
ID=51538441
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201480026088.2A Active CN105189786B (zh) | 2013-03-15 | 2014-03-15 | 用作治疗癌症的疗法的靶标的falz |
Country Status (10)
Country | Link |
---|---|
US (2) | US9920377B2 (zh) |
EP (1) | EP2971129B1 (zh) |
JP (1) | JP6566933B2 (zh) |
CN (1) | CN105189786B (zh) |
AU (1) | AU2014233198B2 (zh) |
CA (1) | CA2907184C (zh) |
ES (1) | ES2672989T3 (zh) |
HK (1) | HK1218868A1 (zh) |
NZ (1) | NZ712300A (zh) |
WO (1) | WO2014145254A2 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ755835A (en) | 2017-01-17 | 2023-12-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
JP7270912B2 (ja) * | 2017-05-22 | 2023-05-11 | 東ソー株式会社 | アドレノメデュリン濃度変動による予後予測の情報提供方法及びその試薬 |
CN108465108B (zh) * | 2018-03-12 | 2020-07-07 | 上海宇玫博生物科技有限公司 | 一种预防或治疗脑胶质瘤的特异性基因靶点 |
CN108486060B (zh) * | 2018-03-12 | 2021-09-14 | 绍兴优铭生物科技有限公司 | 一种用于***的外泌体及其制备方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100145131A1 (en) * | 2007-05-01 | 2010-06-10 | Helena Grinberg-Rashi | Methods and kits for predicting cancer metastasis |
WO2012055879A1 (en) * | 2010-10-27 | 2012-05-03 | Glaxo Group Limited | Method of treatment by inhibition of baz1b |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
EP0341904B1 (en) | 1988-05-09 | 1995-03-29 | Temple University of the Commonwealth System of Higher Education | Method for predicting the effectiveness of antineoplastic therapy in individual patients |
AU631802B2 (en) | 1988-06-14 | 1992-12-10 | Cetus Oncology Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
AU654811B2 (en) | 1990-03-20 | 1994-11-24 | Trustees Of Columbia University In The City Of New York, The | Chimeric antibodies with receptor binding ligands in place of their constant region |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
AU660297B2 (en) | 1990-11-09 | 1995-06-22 | Stephen D. Gillies | Cytokine immunoconjugates |
ES2202310T3 (es) | 1991-12-13 | 2004-04-01 | Xoma Corporation | Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos. |
CA2140638C (en) | 1992-07-24 | 2010-05-04 | Raju Kucherlapati | Generation of xenogeneic antibodies |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
US5830698A (en) | 1997-03-14 | 1998-11-03 | Idec Pharmaceuticals Corporation | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
EP1235842A4 (en) | 1999-10-15 | 2003-04-23 | Univ Massachusetts | GENESIS OF THE RNA INTERFERENCE PATH AS AID OF TARGETED GENTIAN INTERFERENCE |
GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
EP1732581A4 (en) | 2003-06-20 | 2008-06-04 | Univ California San Diego | POLYPEPTIDE TRANSDUCTION AND FUSOGENIC PEPTIDES |
CA2638915A1 (en) | 2006-02-10 | 2007-08-23 | The Regents Of The University Of California | Transducible delivery of sirna by dsrna binding domain fusions to ptd/cpps |
US20080009552A1 (en) * | 2006-03-23 | 2008-01-10 | Craig Pennell | Markers of pre-term labor |
EP2046964B1 (en) | 2006-07-12 | 2018-07-04 | The Regents of The University of California | Transducible delivery of nucleic acids by reversible phosphotriester charge neutralization protecting groups |
WO2008097908A2 (en) | 2007-02-05 | 2008-08-14 | Dana-Farber Cancer Institute, Inc. | Methods of diagnosing and prognosing lung cancer |
US8829173B2 (en) | 2008-09-26 | 2014-09-09 | Tocagen Inc. | Recombinant vectors |
EP2366162A1 (en) * | 2008-11-18 | 2011-09-21 | Collabrx, Inc. | Individualized cancer treatment |
US20140066410A1 (en) | 2011-02-23 | 2014-03-06 | Icahn School Of Medicine At Mount Sinai | Inhibitors of bromodomains as modulators of gene expression |
US20160078168A1 (en) * | 2012-02-13 | 2016-03-17 | Splicingcodes.Com | Fusion transcript detection methods and fusion transcripts identified thereby |
IN2014DN07812A (zh) * | 2012-02-27 | 2015-05-15 | British Columbia Cancer Agency | |
JP2015529073A (ja) | 2012-08-20 | 2015-10-05 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 生物可逆性基を有するポリヌクレオチド |
US20140235456A1 (en) * | 2012-12-17 | 2014-08-21 | Virginia Tech Intellectual Properties, Inc. | Methods and Compositions for Identifying Global Microsatellite Instability and for Characterizing Informative Microsatellite Loci |
-
2014
- 2014-03-15 EP EP14764616.0A patent/EP2971129B1/en active Active
- 2014-03-15 WO PCT/US2014/029986 patent/WO2014145254A2/en active Application Filing
- 2014-03-15 CA CA2907184A patent/CA2907184C/en active Active
- 2014-03-15 NZ NZ712300A patent/NZ712300A/en unknown
- 2014-03-15 AU AU2014233198A patent/AU2014233198B2/en active Active
- 2014-03-15 CN CN201480026088.2A patent/CN105189786B/zh active Active
- 2014-03-15 ES ES14764616T patent/ES2672989T3/es active Active
- 2014-03-15 US US14/775,665 patent/US9920377B2/en active Active
- 2014-03-15 JP JP2016503299A patent/JP6566933B2/ja active Active
-
2016
- 2016-06-15 HK HK16106910.6A patent/HK1218868A1/zh unknown
-
2018
- 2018-03-19 US US15/925,500 patent/US10526662B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100145131A1 (en) * | 2007-05-01 | 2010-06-10 | Helena Grinberg-Rashi | Methods and kits for predicting cancer metastasis |
WO2012055879A1 (en) * | 2010-10-27 | 2012-05-03 | Glaxo Group Limited | Method of treatment by inhibition of baz1b |
Non-Patent Citations (6)
Title |
---|
A molecular signature of metastasis in primary solid tumors;Sridhar Ramaswamy等;《Nature Genetics》;20021209;第33卷(第1期);摘要,第49页左栏最后1段、右栏第3段,第50页图1 * |
A Novel Translocation Breakpoint within the BPTF Gene Is Associated with a Pre-Malignant Phenotype;Yosef Buganim等;《PLOS ONE》;20100311;第5卷(第3期);e9657 * |
Bromodomains as therapeutic targets;Susanne Muller等;《Expert Reviews in Molecular Medicine》;20110913;e29 * |
Expression of BRCA1 and FAC1 in primary sporadic breast cancers;Kristen K. White等;《The FASEB Journal》;20080331;第22卷(第1期);Supplement 898.26 * |
Identification and Characterization of BPTF, a Novel Bromodomain Transcription Factor;Michael H. Jones等;《Genomics》;20000101;第63卷(第1期);第35-39页 * |
Pleckstrin homology domain-interacting protein (PHIP) as a marker and mediator of melanoma metastasis;David De Semir等;《PNAS》;20120417;第109卷(第18期);第7067-7072页 * |
Also Published As
Publication number | Publication date |
---|---|
EP2971129A2 (en) | 2016-01-20 |
EP2971129A4 (en) | 2016-10-26 |
CN105189786A (zh) | 2015-12-23 |
EP2971129B1 (en) | 2018-05-09 |
NZ712300A (en) | 2020-07-31 |
JP6566933B2 (ja) | 2019-08-28 |
ES2672989T3 (es) | 2018-06-19 |
WO2014145254A3 (en) | 2014-12-18 |
US20180274041A1 (en) | 2018-09-27 |
HK1218868A1 (zh) | 2017-03-17 |
US9920377B2 (en) | 2018-03-20 |
CA2907184A1 (en) | 2014-09-18 |
AU2014233198A1 (en) | 2015-10-08 |
US20160024590A1 (en) | 2016-01-28 |
CA2907184C (en) | 2022-12-06 |
US10526662B2 (en) | 2020-01-07 |
CN105189786A8 (zh) | 2018-01-12 |
JP2016525874A (ja) | 2016-09-01 |
WO2014145254A2 (en) | 2014-09-18 |
AU2014233198B2 (en) | 2019-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5922913B2 (ja) | 遺伝子発現の阻害に関する方法および組成物 | |
Okusha et al. | The intranuclear PEX domain of MMP involves proliferation, migration, and metastasis of aggressive adenocarcinoma cells | |
US10526662B2 (en) | FALZ for use as a target for therapies to treat cancer | |
CN109844536A (zh) | 预测对pd-1轴抑制剂的响应 | |
US20220112498A1 (en) | Methods for diagnosing and treating metastatic cancer | |
Walter et al. | Gain of chromosome 7 by chromogenic in situ hybridization (CISH) in chordomas is correlated to c-MET expression | |
TW201628655A (zh) | 泛fgfr抑制劑的用途及鑑定適合以泛fgfr抑制劑治療之癌症病患的方法 | |
CA3108172A1 (en) | Microrna-based therapy targeted against lcp-1 positive cancers | |
Li et al. | CPNE1 silencing inhibits cell proliferation and accelerates apoptosis in human gastric cancer | |
ES2873377T3 (es) | Procedimientos y composiciones farmacéuticas para el tratamiento de cáncer de pulmón | |
JP2009516823A (ja) | Satb1:形態形成および腫瘍転移の決定因子 | |
CN115997122A (zh) | 类维生素a与癌治疗剂的组合疗法有效的癌患者的选择方法、及类维生素a与癌治疗剂的组合药物 | |
JP2015525563A (ja) | Rac変異体を含む組成物、及びその使用方法 | |
DK2257299T3 (en) | Modulation of SRPX2-mediated angiogenesis | |
González-Gualda et al. | A tumour-promoting senescent secretome triggered by platinum chemotherapy exploits a targetable TGFβR1/Akt-mTOR axis in lung cancer | |
US10570398B2 (en) | Methods and compositions involving transmembrane and coiled-coil domains 3 (TM-CO3) in cancer | |
JP6632074B2 (ja) | 癌細胞増殖抑制剤、癌細胞移動抑制剤、及び医薬 | |
Mengensatzproduktion et al. | 134th Congress of the German Society of Surgery (DGCH). March 21-24, 2017, Munich, Germany: Abstracts | |
KR20200118931A (ko) | 저산소 환경에서 유발되는 암의 전이 억제용 조성물 | |
KR20190005727A (ko) | 난소과립막세포암 또는 자궁내막암의 진단 및 치료를 위한 마이크로rna-1236의 용도 | |
Paul et al. | Targeting Gastrin-Releasing Peptide Suppresses Neuroblastoma Progression via Upregulation of | |
Baker | Investigating the effects of Chromosome 21 genes on pathological angiogenesis | |
JP2012530120A (ja) | 薬剤およびその使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1218868 Country of ref document: HK |
|
CI02 | Correction of invention patent application |
Correction item: Classification number Correct: C12Q 1/68(2006.01)|G01N 33/574(2006.01)|A61K 48/00(2006.01)|A61P 35/00(2006.01) False: A99Z 99/00(2006.01) Number: 51 Page: The title page Volume: 31 |
|
CI02 | Correction of invention patent application | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1218868 Country of ref document: HK |